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Abstract
Background Germline mutations in the genes BRCA1  and
BRCA2  account for only a proportion of hereditary breast
cancer, suggesting that additional genes contribute to
hereditary breast cancer. Recently a heterozygous variant in the
ataxia–telangiectasia mutated (ATM) gene, IVS10-6T→G, was
reported by an Australian multiple-case breast cancer family
cohort study (the Kathleen Cuningham Foundation Consortium
for Research into Familial Breast Cancer) to confer a substantial
breast cancer risk. Although this variant can result in a truncated
ATM product, its clinical significance as a high-penetrance
breast cancer allele or its role as a low-penetrance risk-modifier
is controversial.
Methods We determined the frequency of ATM IVS10-6T→G
variants in a cohort of individuals affected by breast and/or
ovarian cancer who underwent BRCA1 and BRCA2 genetic
testing at four major Australian familial cancer clinics.
Results Seven of 495 patients (1.4%) were heterozygous for
the IVS10-6T→G variant; the carrier rate in unselected
Australian women with no family history of breast cancer is
reported to be 6 of 725 (0.83%) (P = 0.4). Two of the seven
probands also harboured a pathogenic BRCA1 mutation and
one patient had a BRCA1  unclassified variant of uncertain
significance.
Conclusion These findings indicate that the ATM IVS10-6T→G
variant does not seem to occur at a significantly higher
frequency in affected individuals from high-risk families than in
the general population. A role for this variant as a low-
penetrance allele or as a modifying gene in association with
other genes (such as BRCA1) remains possible. Routine testing
for ATM IVS10-6T→G is not warranted in mutation screening of
affected individuals from high-risk families.
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Introduction
Germline mutations in the two major breast cancer suscep-
tibility genes, BRCA1  and  BRCA2  (MIM113705 and
600185), are frequently found in families containing multi-
ple individuals affected by breast and ovarian cancer [1].
However, BRCA1 and BRCA2 mutations are only identi-
fied in about 15–20% of multiple-case families affected by
breast cancer alone [1,2]. Other breast cancer-predispos-
ing genes might account for a proportion of the remaining
cases.
The  ATM  (ataxia–telangiectasia mutated) gene (MIM
208900, 607585), whose product has a central role in
DNA repair after damage induced by ionising radiation
[3,4] and phosphorylates BRCA1 [5,6], has been pro-
posed as one such candidate breast cancer-predisposing
A–T, ataxia–telangiectasia; ATM = ataxia–telangiectasia mutated; GHSV = Genetic Health Services Victoria; RMH = Royal Melbourne Hospital; 
SAFCS = South Australian Familial Cancer Service; WH = Westmead Hospital.Breast Cancer Research    Vol 6 No 4    Lindeman et al.
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gene. Individuals harbouring homozygous (or compound
heterozygous) deleterious mutations in the ATM  gene
develop ataxia–telangiectasia (A–T), which is character-
ised by progressive cerebellar degeneration, telangiecta-
sia, immunodeficiency, extreme sensitivity to ionising
radiation and a predisposition to lymphoid malignancies
[7]. Most pathogenic ATM mutations described so far (now
in excess of 300) result in truncating mutations that pro-
duce little or no detectable ATM protein, but pathogenic
missense mutations have also been described. About 1%
of the population are asymptomatic heterozygous carriers.
However, because the ATM protein forms high-molecular-
mass complexes, it is conceivable that heterozygous mis-
sense mutations (or certain truncating mutations) could
have a dominant-negative effect, interfering with the func-
tion of the normal allele and thereby resulting in an
increased predisposition to cancer [8].
Clinical observation and epidemiological studies since the
1970s have shown that blood relatives of A–T patients
seem to be at increased risk for breast cancer, suggesting
that heterozygosity for mutations in the ATM gene might
predispose to breast cancer [9,10]. After the identification
of the gene in 1995 [7], several studies demonstrated an
association between ATM  heterozygosity and increased
risk for breast cancer [11-15]. However, other studies have
failed to demonstrate an association [16-18], concluding
that the contribution of ATM  heterozygosity to familial
breast cancer is minimal. It is difficult to reconcile the differ-
ent outcomes of these studies because they differed in
sample size, in subject selection criteria, and in the muta-
tion detection methods used.
A recent study of multiple-case breast cancer families in
Australia suggested that two ATM  variants,  ATM
7271T→G and IVS10-6T→G, confer a substantial risk for
breast cancer in families with multiple cases [19]. The ATM
7271T→G missense variant was subsequently not
detected in two large independent cohorts of breast can-
cer families [20,21], indicating that the variant is of limited
clinical significance. The ATM IVS10-6T→G variant leads
to incorrect splicing at exon 11 and results in a truncated
ATM product [22]. In the Australian study, this variant was
detected in 2 of 76 (2.6%) breast cancer patients with a
strong family history of breast cancer, 0 of 268 breast can-
cer patients without a family history of the disease, and 0 of
68 women with no personal or family history of breast can-
cer [19]. In the two families with this variant, the penetrance
(in terms of breast cancer risk) was estimated to be 78%
(95% confidence interval 36–99%) by 70 years of age. An
earlier study had also demonstrated an association
between this variant and breast cancer risk [22]. However,
three subsequent studies in North America and Europe
failed to identify a significant role for this variant in heredi-
tary or sporadic breast cancer [20,21,23]. Nevertheless, it
has been argued that the ATM IVS10-6T→G allele repre-
sents a biologically and clinically significant variant
because ATM kinase activity is reduced to 25–40% in het-
erozygous cells [19].
The possibility that ATM IVS10-6T→G could be a high-
penetrance breast cancer susceptibility allele, or even a
low-penetrance risk-modifying allele, has major ramifica-
tions for genetic testing and clinical management of individ-
uals with a hereditary predisposition to breast and ovarian
cancer. Because the association had been made in a
cohort of (ethnically diverse) multiple-case Australian fami-
lies, we determined the frequency and relevance of this var-
iant in an independent series of families from Australian
familial cancer clinics. We compared the frequency of the
ATM IVS10-6T→G variant in affected individuals undergo-
ing genetic testing for BRCA1 and BRCA2 at four major
Australian familial cancer clinics with the carrier rate in Aus-
tralian women without a family history of breast cancer.
Materials and methods
Samples
Patients who had been affected by either breast and/or
ovarian cancer and were index cases within a family that
had initiated BRCA1 and BRCA2 mutation detection were
ascertained from four Australian familial cancer clinics:
Genetic Health Services Victoria (GHSV), Melbourne, the
Royal Melbourne Hospital (RMH), Melbourne, the South
Australian Familial Cancer Service (SAFCS), Adelaide, and
Westmead Hospital (WH), Sydney. For GHSV and RMH,
the series included peripheral blood leucocyte genomic
DNA samples collected between July 1999 and June 2003
(inclusive), for which retrospective patient (or next of kin)
consent was obtained [48 of 59 (81%) and 85 of 97
(88%), respectively]. For SAFCS and WH, a consecutive
series from probands, for whom testing at that stage had
not detected a BRCA1 or BRCA2 mutation, was screened
for the ATM IVS10-6T→G variant (201 and 130 samples,
respectively). Testing was subsequently extended at WH
to include BRCA1 affected mutation carriers (31 samples).
Approval to conduct ATM testing was obtained from each
relevant institutional ethics committee, unless the standard
clinical genetic testing consent form covered such testing.
Affected women's families were categorised as being at
potentially high, moderate or average risk for developing
breast cancer on the basis of family history, according to
the National Health and Medical Research Council (Aus-
tralia) guidelines [24], as follows.
Potentially high risk was defined as the presence of at least
two first-degree or second-degree relatives on one side of
a family diagnosed with breast or ovarian cancer (including
the patient) plus at least one of the following high-risk fea-
tures: additional relative(s) with breast or ovarian cancer,Available online http://breast-cancer-research.com/content/6/4/R401
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breast cancer diagnosed before the age of 40 years, ovar-
ian cancer diagnosed before the age of 50 years, bilateral
breast cancer, breast and ovarian cancer in the same
woman, Jewish ancestry, or breast cancer in a male relative.
Moderate risk was defined as one or two first-degree rela-
tives diagnosed with breast cancer (including the patient)
before the age of 50 years, two first-degree or second-
degree relatives on the same side of the family with breast
or ovarian cancer, or one first-degree relative with ovarian
cancer before the age of 50 years (in all cases without addi-
tional high-risk features). Standard risk was defined as the
affected woman falling outside either of the other two risk
categories.
Mutation screening
Samples were screened for the ATM IVS10-6T→G variant
essentially as described previously [19]. Briefly, a 193-
base-pair fragment spanning the IVS10-6 region was
amplified from genomic DNA by polymerase chain reaction
with the primers 5'-ACAGCGAAACTCTGGCTCAAA-3'
and 5'-TGATCTTTTATTACTTCCCAGCCTAGT-3'.
Because the T→G variant creates a novel RsaI restriction
site, heterozygous carriers were detected by RsaI restric-
tion digest, which produces 58-base-pair and 135-base-
pair variant-specific fragments in addition to the wild-type
193-base-pair fragment. Fragments were separated and
detected on either a 12% SDS-polyacrylamide gel or a
1.5% agarose gel. Alternatively, the restriction fragments
were separated by denaturing high-performance liquid
chromatography (details available from the authors on
request). A positive control genomic sample was kindly
provided by Dr G Chenevix-Trench (Queensland Institute
of Medical Research, Brisbane, Australia). For sequencing,
independently amplified polymerase chain reaction prod-
ucts were generated and confirmed by automated
sequencing with the ABI Prism BigDye Terminator Cycle
Sequencing Kit (Perkin Elmer).
Statistical analysis
Two-tailed P values were generated with Fisher's Exact
Test. In accordance with convention, P < 0.05 was consid-
ered significant.
Results and discussion
To investigate the frequency of the ATM IVS10-6T→G var-
iant in patients at high probability of carrying a gene predis-
posing them to breast cancer, we ascertained 495 patients
who had attended one of four familial cancer clinics located
in three Australian States. These patients had been
affected by either breast or ovarian cancer and had under-
gone genetic testing for BRCA1 and BRCA2 mutations. In
most cases (90.7%), the family was classified as 'poten-
tially high risk' for breast and/or ovarian cancer predisposi-
tion [24]. A small proportion (7.5%) were categorised as
being in the moderate risk group, although these generally
exhibited unusual features (such as breast and ovarian can-
cer in a single individual in the absence of a family history),
and insufficient information on risk was available for the
remaining 1.8%. The proportion of families in the different
risk categories was similar at the four centres (Table 1; data
not shown). For patients from GHSV, RMH and WH, the
average age of breast cancer diagnosis of the proband was
45 years (range 22–78) and an average of 3.4 breast can-
cers and 0.42 ovarian cancers were documented per fam-
ily. Of the potentially high-risk kindreds, the majority (71%)
of families contained breast-only cancer cases, whereas
breast and ovarian cancers were noted in the remaining
families. For SAFCS families, the average age of breast
cancer diagnosis for the proband was 48 years, and an
average of 3.2 breast cancers and 0.25 ovarian cancers
were documented per family. The mean predictions for
GHSV and RMH patients carrying a BRCA1 or BRCA2
mutation were 0.22 and 0.19, respectively, as determined
by either the BRCAPRO or the MYRIAD II statistical model
[25].
We screened probands from non-BRCA1/BRCA2 families
in whom no mutation had been identified at the time (n =
464) and probands with known BRCA1 mutations (WH
cohort, n = 31). Of the 495 probands screened, 7 (1.4%)
were found to be heterozygous for the ATM IVS10-6T→G
variant. Four of these were ascertained through SAFCS
and one from each of the other centres (Table 2). None of
these ATM heterozygotes had been reported in the study
by Chenevix-Trench and colleagues [19]. Their age at diag-
nosis, family histories and family risk status were quite
diverse (Table 3). Their mean age at first cancer diagnosis
was 53 years (range 35–62). None had a history of prior
radiation exposure. Three of the seven individuals had a
family history of breast/ovarian cancer, one a family history
of breast/thyroid cancer, and the remaining three families
had a history of breast cancer alone. Three heterozygous
individuals were from moderate-risk families. No hetero-
zygous carriers had clinical features attributable to A–T
such as ataxia, telangiectasia or immunodeficiency.
BRCA1 and BRCA2 genetic testing results were subse-
quently available for all seven individuals. Two were found
to harbour pathogenic truncating mutations in BRCA1
(both from families with a history of breast/ovarian cancer),
and one a BRCA1 variant of uncertain significance (from a
moderate-risk family). For both BRCA1 and ATM IVS10-
6T→G carriers (probands 1 and 7 in Table 3), the his-
topathological features of the primary breast and ovarian
cancers were consistent with the phenotype associated
with  BRCA1  tumours [26,27]. The breast cancer from
proband 1 was a grade III oestrogen receptor-negative and
progesterone receptor-negative infiltrating ductal carci-
noma with lymphocytic infiltrate and pushing margins. TheBreast Cancer Research    Vol 6 No 4    Lindeman et al.
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ovarian cancer from proband 7 was a high-grade serous
carcinoma with marked nuclear pleomorphism, together
with a large cyst containing a serous cystadenoma and
smaller cysts containing borderline malignancy. There were
no remarkable histopathological features in the tumours
from the other five cases, including proband 4 (with the
BRCA1 unclassified variant). Thus, the ATM IVS10-6T→G
allele was not apparently associated with a distinct tumour
phenotype.
The frequency (1.4%) of the ATM IVS10-6T→G variant is
somewhat greater than the reported frequency of 6 of 725
(0.8%) for a cohort of Australian women ascertained with-
out a personal or family history of breast cancer [28]; how-
ever, this difference is not significantly different (P = 0.4).
This frequency is also similar to control cases reported in
Dutch, German and Austrian populations [21,22,29,30],
and a recent study in the USA [23], although minor differ-
ences might be due to population heterogeneity (Table 4).
These results are consistent with the observation that the
ATM  IVS10-6T→G variant is an ancient mutation that
might be widely distributed across Europe, the Middle East
and western Asia [30]. In the study by Chenevix-Trench
and colleagues, analysis was performed on non-BRCA1/
BRCA2 cases containing more than three breast cancers
per family, and families with male breast cancer(s) were
excluded [19]. By restricting the analysis of our samples
(GHSV, RMH, WH) to those with more than three breast or
ovarian cancers within a family and no cases of male breast
cancer, the frequency was 2 of 197 (1.0%), but both cases
also carried pathogenic BRCA1 mutations. The basis for
the increased frequency reported for kindreds in the Kath-
leen Cuningham Foundation Consortium for Research into
Familial Breast Cancer is unclear, although a subsequent
report now suggests a lower frequency at 6 of 385 (1.6%)
[28].
It was not feasible to evaluate the co-segregation of the
ATM IVS10-6T→G allele with the breast or ovarian can-
cers in each kindred in our cohort. In the two ATM IVS10-
6T→G families reported by Chenevix-Trench and col-
leagues, carriers had an estimated disease penetrance of
78% (confidence interval 36–99%) to age 70 years, equiv-
alent to a 26-fold increased risk [19]. However, it is note-
Table 1
Characteristics of index cases and families
Characteristic GHSV, RMH and WHa SAFCS Total
Total number of families 294 201 495
Average number of female breast cancer cases per family 3.4 3.2
Average number of ovarian cancer cases per family 0.42 0.25
Average age of index case breast cancer diagnosis (years) 45.1 48.2
High risk 270 (91.8%) 179 (89.0%) 449 (90.7%)
With breast and ovarian cancer cases 77 (26.2%)
With breast cancer cases and high-risk featuresb 142 (48.3%)
With breast cancer cases and no high-risk featuresc 51 (17.3%)
Moderate risk 22 (7.5%) 15 (7.5%) 37 (7.5%)
Risk status not known 2 (0.7%) 7 (3.5%) 9 (1.8%)
aWH cases (n = 161) included 31 known BRCA1 carriers. bAt least two breast cancers, one of which has the following features: age onset 40 
years or less, bilateral (or multifocal) disease, male breast cancer, Ashkenazi ancestry. cThree or more breast cancers with no high-risk features.
Table 2
Frequency of ATM IVS10-6T→G variant carriers
Site Frequency %
Genetic Health Services Victoria (GHSV) 1/48 2.0
Royal Melbourne Hospital (RMH) 1/85 1.2
SA Familial Cancer Service (SAFCS) 4/201 2.0
Westmead Hospital (WH) 1/161 0.6
Total 7/495 1.4Available online http://breast-cancer-research.com/content/6/4/R401
R405
Table 3
ATM IVS10-6T→G variant carriers: features of family history and BRCA1 and BRCA2 status
Proband Institution Index case 
(site, age dx)
Risk BRCA1 BRCA2 Features of family history, first, second degree and other 
relatives (site, age dx)
1 GHSV Br, 37 High 5055delG (STOP 1657) Normal Breast/ovarian
First degree: Mo (Br, 41; Ov, 42)
Second degree: Mat Aunt (Ov, 46)
Other (Mat): 2nd Cous fem (Br, 46–50); GrGM (Br, 86)
2 RMH Br, 62; Ov, 62 Mod Normal Normal Breast/ovarian
First degree: Sis (?Oc Mel, 61)
Second degree: Mat Unc (NK, 40s)
3 SAFCS Br, 51 Mod Normal Normal Breast
First degree: Mo (Br, 51); Son (CRC, 24)
4 SAFCS Br, 35 Mod 4654G→T (S1512I, 
unclassified variant)
Normal Breast
First degree: Mo (Br, 46)
5 SAFCS Br, 68 High Normal Normal Breast/thyroid
First degree: Mo (Br, 64); Bro (Pr, 64)
Second degree: Nie (Br, 35; CRC, 42); Nie (Br, 35; Br, 
51; Thy, 51); Mat GM (Br, 72)
Other (Mat): 1st Cous fem (Br, 49), fem (Br multifocal), m 
(Pr, 68); 1st cous once removed fem (Br, 46; Br, 49), m 
(Thy, NK); 1st cous twice removed (Leuk, 14)
6 SAFCS Br, 64 High Normal Normal Breast
First degree: Mo (Br, 53); Sis (Br, 44); Dau (Mel, 38)
Second degree: Mat Aunt (Br, 78); Mat GM (Bil, 75 and 
92)
7 WH Ov, 56 High 2080insA (STOP 762) Normal Breast/ovarian
Second degree: Pat GM (Br, 63)
Other (Pat): first Cous fem (Ov, 54), (Br, 53), (Br, 63); 1st 
Cous once removed (Ov, NK), (Ov, NK); 2nd Cous fem 
(Br, 50s), (Br, 50s)
Age dx, age in years at diagnosis; Bil, biliary; Br, breast; Bro, brother; Cous, cousin; CRC, colorectal cancer; Dau, daughter; fem, female; GHSV, 
Genetic Health Services Victoria;GM, grandmother; Gr, great; Leuk, leukemia; m, male; mat, maternal; Mel, melanoma; Mo, mother; Nie, niece; 
NK, not known; Oc Mel, ocular melanoma; Ov, ovarian; Pr, prostate; Pat, paternal; RMH, Royal Melbourne Hospital; SAFCS, SA Familial Cancer 
Service; Sis, sister; Thy, thyroid; Unc, uncle; WH, Westmead Hospital.
Table 4
Studies on the ATM IVS10-6T→G variant in breast cancer
Reference (year) Location Frequency of cases with 
mutation
Frequency of controls 
with mutation
Comments
[22] (2000) The Netherlands 3/82 (3.7%) 2/268 (0.7%) Cases aged less than 45 years
[29] (2001) Germany 7/1000 (0.7%) 3/500 (0.6%) Unselected cases
[32] (2002) USA 0/43 1/43 (2.3%) Unselected cases
[19] (2002) Australia and New Zealand 2/76 (2.6%)
4/144 (2.8%)a
0/68 Strong FHx, non-BRCA1/2, male breast 
cancer excluded
[20] (2002) Sweden and Czech 
Republic
2/768 (0.3%) 5/557 (0.2%) Unselected cases and FHx (non-BRCA1/2)
[30] (2003) The Netherlands 3/193 (1.6%)
3/233 (1.3%)
2/268 (0.7%) FHx, non-BRCA1/2
Cases aged less than 45 years
[23] (2003) USA and Denmark 1/511 (0.2%) 8/638 (1.3%) Bilateral versus unilateral breast cancer 
(control group) unselected for FHx




4/543 (0.7%) Non-BRCA1/2 families
BRCA1/2 families
This study Australia 7/495 (1.4%) 6/725 (0.8%) [28]
a2 of 76 non-BRCA1/BRCA2 families reported. A manuscript note added in proof reported an additional 2 families of a further 68 non-BRCA1/
BRCA2 families. FHx, family historyBreast Cancer Research    Vol 6 No 4    Lindeman et al.
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worthy that the LOD (logarithm of odds) score of 1.18 for
linkage with ATM  fell well short of standard criteria for
significance.
A recent study by Szabo and colleagues evaluated five
ATM  IVS10-6T→G families with non-BRCA1/BRCA2
breast cancer and concluded that the variant did not confer
an increase in risk for breast cancer. That study also did not
observe an increase in the frequency of the ATM IVS10-
6T→G variant among BRCA1/BRCA2-positive families
(0.5%) [21]. In our study, two of the seven ATM IVS10-
6T→G heterozygotes harboured pathogenic BRCA1
mutations and a further proband carried a BRCA1 unclas-
sified variant. This possible association is intriguing
because ATM is known to phosphorylate BRCA1 [5,6],
and BRCA1 has recently been shown to be required for
certain ATM functions, including the phosphorylation of
substrates such as p53 and Chk2 that influence cell cycle
arrest and apoptosis after DNA damage [31]. Further inves-
tigation of this variant as a low-penetrance modifier allele
might be warranted.
In contrast, it has been argued that ATM IVS10-6T→G is a
high-penetrance allele but our study has failed to support
this view. Although this truncating variant has been postu-
lated to act in a dominant-negative manner [19], the identi-
fication of a truncated product in heterozygotes has not
been reported, suggesting that the product undergoes
rapid degradation. It is known that the variant allele pro-
duces less than 10% of full-length ATM mRNA [29]; it
therefore remains possible that heterozygous carriers sim-
ply display reduced ATM levels and that the residual ATM
kinase activity is sufficient for maintaining normal cellular
responses under most circumstances.
Conclusion
The frequency of the ATM IVS10-6T→G splice-site variant
was similar in affected individuals from our clinic-based
cases with a strong family history to that reported for
individuals with no personal or family history of breast or
ovarian cancer. Screening for the IVS10-6T→G variant in a
familial cancer clinic setting is therefore unlikely to be of
clinical significance. The relatively high prevalence of this
variant among unaffected Europeans [30] further under-
mines its relevance in a clinical context. However, it remains
plausible that the ATM IVS10-6T→G variant could function
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